IFNL3 and Hepatic fibrosis: Future studies should include examination of earlier time points just after HCV treatment initiation, the impact of underlying host genetics (i.e. IL28b genotype), the effect of new HCV protease and polymerase inhibitors, and potential correlations between biomarker levels and histological or clinical degrees of liver fibrosis or dysfunction.